Skip to content
thestock.space

As of 6 Nov 2026, Emmessar Biotech & Nutrition trades at 28.5× trailing earnings, below the industry P/E of 28.7×, and the shares are 33% below their 52-week high. Sales and net profit fell 29% and 4.7% a year over 3 years; its ROCE of 6.4% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, though net profit is above operating profit, which points to a one-off gain. It is a small-cap company with a market cap of ₹11 Cr, ranked 148th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 27% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹22.49
Day high
₹22.49
Day low
₹22.04
Prev. close
₹22.50
Volume
22

Health check

1 fair · 4 to check
  • ReturnsBehind

    −27.2% over a year, better than 0 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthShrinking

    Sales −28.6%, profit −4.7% a year over 3 years.

  • ProfitabilityWeak

    ROCE 6.4% vs peer median 17.9%.

  • Balance sheetFair

    Piotroski 6 of 9.

  • Red flags5 to check

    Return on equity is low at 5.2%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹11 Cr, #148 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹2 Cr · profit ₹0 Cr
Market cap
₹11 Cr
Small cap
P/E
28.5
Industry 28.7
Price to book
1.34
Peers 4.99
Dividend yield
0.00%
ROE
5.2%
Peers 14.7%
ROCE
6.4%
Peers 17.9%
Debt to equity
n/a
Debt ₹0.00 Cr
EPS (TTM)
₹0.79
OPM (TTM)
−423.9%
Net margin 21.2%
Sales growth
−36.1%
Latest quarter vs a year ago
Profit growth
−23.2%
Latest quarter vs a year ago
Price to sales
5.65
EV/EBITDA 14.3

Strengths and risks

Strengths

  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 5.2%.
  • Quarterly profit down 23.2% on a year ago.
  • Quarterly sales down 36.1% on a year ago.
  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.
  • 33% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Emmessar Biotech & Nutrition

Emmessar Biotech & Nutrition Limited, a healthcare company, provides healthcare and nutritional products in India and internationally. The company operates through Healthcare and Rent on Lease Land segments. It also offers CalmCream, a multi-functional skin cream; Calm Cream RESQ, a skin cream used for burns from sun, radiation, heat and chemicals; Cute-N-Comely, a cosmetic skin cream; MagiCream, a cream used for post-surgical scars; and Muscle Flex Gel,…

Headquarters
Mumbai
Employees
18
Sector
Healthcare
ISIN
INE634B01016
Website
ebnl.org

Price range

52 weeks

₹18.42₹33.38

Today

₹22.04₹22.49
Avg volume (3M)
1.5K
1-year return
minus 27.2%
From 52-week high
minus 32.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
EMMESSAEmmessar Biotech & Nutrition22.49minus 0.04%1128.51.346.4%5.2%−423.9%−28.6%−4.7%0.00%minus 27.2%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
0.10.10.10.10.1
0.40.50.40.50.4
−0.3−0.4−0.3−0.4−0.4
−298.9%−406.7%−359.4%−396.7%−594.9%
0.50.50.50.50.5
00000
00000
0.20.10.10.10.2
26.0%18.7%9.3%57.0%19.3%
0.20.10.100.1
0.340.230.230.070.26

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−28.6%
Profit CAGR 3Y
−4.7%
EPS CAGR 3Y
−4.2%
ROE
5.2%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.60.60.4
–minus 45.5%+10.1%minus 39.3%
1.71.61.61.7
−0.7−1.1−1−1.4
−65.7%−194.3%−155.6%−364.7%
1.7222
––00
0.10.10.10.1
0000
10.810.6
47.9%7.8%67.0%24.8%
0.50.70.30.4
–+48.8%minus 57.8%+37.8%
0.991.480.630.87

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5555
1.72.42.73.1
0.10.1––
1.21.21.71.7
7.98.79.49.8
1.41.31.21.1
0000
5.26.26.97.3
1.31.21.31.3
7.98.79.49.8

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
0.40.60.20.3
−0.5−0.6−0.2−0.3
––00
−0.20−00
−0––−0
0.30.60.20.3

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you